Business Description
Vicore Pharma Holding AB
ISIN : SE0007577895
Total Employee Number:
37Compare
Compare
Traded in other countries / regions
VICO.Sweden6Y4.Germany IPO Date
2015-12-10Description
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 23.83 | |||||
Beneish M-Score | -3.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.7 | |||||
3-Year EPS without NRI Growth Rate | 19.9 | |||||
3-Year FCF Growth Rate | 27.3 | |||||
3-Year Book Growth Rate | 4.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.88 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.43 | |||||
9-Day RSI | 74.78 | |||||
14-Day RSI | 67.81 | |||||
3-1 Month Momentum % | 17 | |||||
6-1 Month Momentum % | 3.54 | |||||
12-1 Month Momentum % | 53.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.69 | |||||
Quick Ratio | 12.69 | |||||
Cash Ratio | 12.52 | |||||
Days Sales Outstanding | 90.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -13742.16 | |||||
Net Margin % | -13454.92 | |||||
EBITDA Margin % | -12682.51 | |||||
FCF Margin % | -11510.15 | |||||
OCF Margin % | -11510.15 | |||||
ROE % | -49.29 | |||||
ROA % | -45.43 | |||||
ROIC % | -988.01 | |||||
3-Year ROIIC % | 1712.99 | |||||
ROCE % | -46.32 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 900 | |||||
PB Ratio | 3.58 | |||||
Price-to-Tangible-Book | 3.58 | |||||
EV-to-EBIT | -5.56 | |||||
EV-to-EBITDA | -5.56 | |||||
EV-to-Revenue | 705.24 | |||||
EV-to-Forward-Revenue | 2.29 | |||||
EV-to-FCF | -5.93 | |||||
| Price-to-Net-Current-Asset-Value | 3.59 | |||||
| Price-to-Net-Cash | 3.64 | |||||
Earnings Yield (Greenblatt) % | -18.01 | |||||
FCF Yield % | -11.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vicore Pharma Holding AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 3.527 | ||
| EPS (TTM) (kr) | -1.9 | ||
| Beta | 0.6088 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 46.68 | ||
| 14-Day RSI | 67.81 | ||
| 14-Day ATR (kr) | 0.533662 | ||
| 20-Day SMA (kr) | 11.217 | ||
| 12-1 Month Momentum % | 53.75 | ||
| 52-Week Range (kr) | 7.35 - 14.1 | ||
| Shares Outstanding (Mil) | 281.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vicore Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vicore Pharma Holding AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 51 days | ||
| General meeting for 2026 | 2026-05-06 15:00 | 9.76 (-2.01%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 9.76 (-2.01%) | ||
| Annual report for 2025 | 2026-03-26 | 10.88 (+4.62%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-27 | 10.36 (-0.77%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 11.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 10.74 (+2.09%) | ||
| General meeting for 2025 | 2025-05-06 15:00 | 8.24 (-2.94%) | ||
| First quarter earnings results for 2025 | 2025-05-06 | 8.24 (-2.94%) |
Show
Entries
Vicore Pharma Holding AB Frequently Asked Questions
What is Vicore Pharma Holding AB(OSTO:VICO)'s stock price today?
The current price of OSTO:VICO is kr12.60. The 52 week high of OSTO:VICO is kr14.10 and 52 week low is kr7.35.
When is next earnings date of Vicore Pharma Holding AB(OSTO:VICO)?
The next earnings date of Vicore Pharma Holding AB(OSTO:VICO) is 2026-08-21.
Does Vicore Pharma Holding AB(OSTO:VICO) pay dividends? If so, how much?
Vicore Pharma Holding AB(OSTO:VICO) does not pay dividend.
Press Release
Articles on Vicore Pharma Holding AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers